First- or second-trimester SARS-CoV-2 infection and subsequent pregnancy outcomes.
COVID-19
SARS-CoV-2 infection
fetal or neonatal death
hypertensive disorders of pregnancy
pregnancy
preterm birth
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
21
05
2022
revised:
08
08
2022
accepted:
08
08
2022
pubmed:
16
8
2022
medline:
28
1
2023
entrez:
15
8
2022
Statut:
ppublish
Résumé
SARS-CoV-2 infection during pregnancy is associated with adverse pregnancy outcomes, including fetal death and preterm birth. It is not known whether that risk occurs only during the time of acute infection or whether the risk persists later in pregnancy. This study aimed to evaluate whether the risk of SARS-CoV-2 infection during pregnancy persists after an acute maternal illness. A retrospective cohort study of pregnant patients with and without SARS-CoV-2 infection delivering at 17 hospitals in the United States between March 2020 and December 2020. Patients experiencing a SARS-CoV-2-positive test at or before 28 weeks of gestation with a subsequent delivery hospitalization were compared with those without a positive SAR-CoV-2 test at the same hospitals with randomly selected delivery days during the same period. Deliveries occurring at <20 weeks of gestation in both groups were excluded. The study outcomes included fetal or neonatal death, preterm birth at <37 weeks of gestation and <34 weeks of gestation, hypertensive disorders of pregnancy (HDP), any major congenital malformation, and size for gestational age of <5th or <10th percentiles at birth based on published standards. HDP that were collected included HDP and preeclampsia with severe features, both overall and with delivery at <37 weeks of gestation. Of 2326 patients who tested positive for SARS-CoV-2 during pregnancy and were at least 20 weeks of gestation at delivery from March 2020 to December 2020, 402 patients (delivering 414 fetuses or neonates) were SARS-CoV-2 positive before 28 weeks of gestation and before their admission for delivery; they were compared with 11,705 patients without a positive SARS-CoV-2 test. In adjusted analyses, those with SARS-CoV-2 before 28 weeks of gestation had a subsequent increased risk of fetal or neonatal death (2.9% vs 1.5%; adjusted relative risk, 1.97; 95% confidence interval, 1.01-3.85), preterm birth at <37 weeks of gestation (19.6% vs 13.8%; adjusted relative risk, 1.29; 95% confidence interval, 1.02-1.63), and HDP with delivery at <37 weeks of gestation (7.2% vs 4.1%; adjusted relative risk, 1.74; 95% confidence interval, 1.19-2.55). There was no difference in the rates of preterm birth at <34 weeks of gestation, any major congenital malformation, and size for gestational age of <5th or <10th percentiles. In addition, there was no significant difference in the rate of gestational hypertension overall or preeclampsia with severe features. There was a modest increase in the risk of adverse pregnancy outcomes after SARS-CoV-2 infection.
Sections du résumé
BACKGROUND
SARS-CoV-2 infection during pregnancy is associated with adverse pregnancy outcomes, including fetal death and preterm birth. It is not known whether that risk occurs only during the time of acute infection or whether the risk persists later in pregnancy.
OBJECTIVE
This study aimed to evaluate whether the risk of SARS-CoV-2 infection during pregnancy persists after an acute maternal illness.
STUDY DESIGN
A retrospective cohort study of pregnant patients with and without SARS-CoV-2 infection delivering at 17 hospitals in the United States between March 2020 and December 2020. Patients experiencing a SARS-CoV-2-positive test at or before 28 weeks of gestation with a subsequent delivery hospitalization were compared with those without a positive SAR-CoV-2 test at the same hospitals with randomly selected delivery days during the same period. Deliveries occurring at <20 weeks of gestation in both groups were excluded. The study outcomes included fetal or neonatal death, preterm birth at <37 weeks of gestation and <34 weeks of gestation, hypertensive disorders of pregnancy (HDP), any major congenital malformation, and size for gestational age of <5th or <10th percentiles at birth based on published standards. HDP that were collected included HDP and preeclampsia with severe features, both overall and with delivery at <37 weeks of gestation.
RESULTS
Of 2326 patients who tested positive for SARS-CoV-2 during pregnancy and were at least 20 weeks of gestation at delivery from March 2020 to December 2020, 402 patients (delivering 414 fetuses or neonates) were SARS-CoV-2 positive before 28 weeks of gestation and before their admission for delivery; they were compared with 11,705 patients without a positive SARS-CoV-2 test. In adjusted analyses, those with SARS-CoV-2 before 28 weeks of gestation had a subsequent increased risk of fetal or neonatal death (2.9% vs 1.5%; adjusted relative risk, 1.97; 95% confidence interval, 1.01-3.85), preterm birth at <37 weeks of gestation (19.6% vs 13.8%; adjusted relative risk, 1.29; 95% confidence interval, 1.02-1.63), and HDP with delivery at <37 weeks of gestation (7.2% vs 4.1%; adjusted relative risk, 1.74; 95% confidence interval, 1.19-2.55). There was no difference in the rates of preterm birth at <34 weeks of gestation, any major congenital malformation, and size for gestational age of <5th or <10th percentiles. In addition, there was no significant difference in the rate of gestational hypertension overall or preeclampsia with severe features.
CONCLUSION
There was a modest increase in the risk of adverse pregnancy outcomes after SARS-CoV-2 infection.
Identifiants
pubmed: 35970201
pii: S0002-9378(22)00641-X
doi: 10.1016/j.ajog.2022.08.009
pmc: PMC9374493
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
226.e1-226.e9Subventions
Organisme : NICHD NIH HHS
ID : UG1 HD087230
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040485
Pays : United States
Organisme : NICHD NIH HHS
ID : U24 HD036801
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD027915
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087192
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040544
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD034208
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
JAMA. 2022 Feb 22;327(8):748-759
pubmed: 35129581
MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645
pubmed: 34818318
MMWR Morb Mortal Wkly Rep. 2020 Sep 25;69(38):1347-1354
pubmed: 32970655
Obstet Gynecol. 2019 Jan;133(1):1
pubmed: 30575675
Am J Obstet Gynecol. 2022 Jan;226(1):68-89.e3
pubmed: 34302772
Rev Med Virol. 2021 Sep;31(5):1-16
pubmed: 33387448
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1635-1640
pubmed: 33151917
Placenta. 2021 Sep 1;112:97-104
pubmed: 34329973
Am J Obstet Gynecol. 2021 Dec;225(6):689-693.e1
pubmed: 34454898
Am J Obstet Gynecol. 2021 Dec;225(6):593.e1-593.e9
pubmed: 34364845
Viruses. 2020 Nov 15;12(11):
pubmed: 33203131
CMAJ. 2021 Apr 19;193(16):E540-E548
pubmed: 33741725
Placenta. 2021 Jun;109:72-74
pubmed: 34034016
Obstet Gynecol. 2021 Apr 1;137(4):571-580
pubmed: 33560778
Lancet Digit Health. 2022 Feb;4(2):e95-e104
pubmed: 35034863
Obstet Gynecol. 2014 Jul;124(1):16-22
pubmed: 24901276